Trial Search Results

JSP191 Antibody Targeting Conditioning in MDS/AML Patients Undergoing Hematopoietic Cell Transplantation

This is a Phase 1 study to evaluate the safety and tolerability of an antibody conditioning regimen known as JSP191, in combination with low dose radiation and fludarabine, in patients with Myelodysplastic Syndrome or Acute Myeloid Leukemia undergoing blood stem cell transplantation

Stanford is currently accepting patients for this trial.

Lead Sponsor:

Jasper Therapeutics, Inc.

Stanford Investigator(s):


  • Biological: Humanized anti-CD117 Monoclonal Antibody (JSP191)


Phase 1


Key Inclusion Criteria:

   - AML/MDS as defined by specific criteria, including but not limited to the following

      1. AML in CR, Flt3+ MRD+

      2. AML in CR, Flt3- MRD+

      3. MDS < 5% BM blasts, MID/MRD+

      4. MDS 5 - 10% BM blasts

   - Patients with human leukocyte antigen (HLA) matched related or unrelated donors

   - Adequate end organ function as defined in study protocol

Key Exclusion Criteria:

   - Patients with any acute or uncontrolled infections

   - Patients receiving any other investigational agents

   - Patients with active non-hematologic malignancy

   - Prior allogeneic hematologic cell transplantation

Ages Eligible for Study

18 Years - N/A

Genders Eligible for Study


Now accepting new patients

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Michelle Chin